Baidu
map

Cell Reports:科学家发现埃博拉病毒对免疫系统的早期影响

2017-01-22 佚名 生物谷

NIH的科学家使用一种新的早期埃博拉病毒(EBOV)感染的小鼠模型发现了免疫系统的早期免疫反应如何影响埃博拉病毒的发展。这个模型将有助于找到开发治疗EBOV感染药物的靶点。 来自美国NIH过敏和感染疾病研究所的科学家领导了这项研究,并与来自华盛顿大学和哥伦比亚大学的科学家一起合作完成。 科学家们分析了宿主细胞驱使免疫系统应对EBOV感染的信号通路及免疫系统由此产生的免疫反应。他们主


NIH的科学家使用一种新的早期埃博拉病毒(EBOV)感染的小鼠模型发现了免疫系统的早期免疫反应如何影响埃博拉病毒的发展。这个模型将有助于找到开发治疗EBOV感染药物的靶点。

来自美国NIH过敏和感染疾病研究所的科学家领导了这项研究,并与来自华盛顿大学和哥伦比亚大学的科学家一起合作完成。

科学家们分析了宿主细胞驱使免疫系统应对EBOV感染的信号通路及免疫系统由此产生的免疫反应。他们主要关注了感染后数小时内发生的涉及细胞线粒体抗病毒信号蛋白(MAVS)的信号通路。

科学家们已经知道MAVS发挥着关键的抗EBOV效应,而这项研究是首次在动物模型中检测这个蛋白的作用。尽管许多细胞都可以产生MAVS,但是他们发现巨噬细胞产生的MAVS在控制EBOV感染及由此导致的器官和组织损伤中发挥重要作用。

在他们的实验中,巨噬细胞协调产生了最强烈的免疫反应,并且产生了1型干扰素,而1型干扰素是一种发挥抗病毒效应的重要蛋白。他们还发现EBOV可以抑制MAVS信号及干扰素的产生,从而引起感染小鼠患病。

为了能够最终开发出相关药物,科学家们将继续深入研究,以阐明MVOS控制的具体免疫反应及其机制,同时研究清除EBOV延缓免疫反应的机制。

原始出处

M Dutta et al.A systems approach reveals MAVS signaling in myeloid cells as critical for resistance to Ebola virus in murine models of infection.Cell Reports.2016

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1650363, encodeId=4f9f165036361, content=<a href='/topic/show?id=9e424155935' target=_blank style='color:#2F92EE;'>#埃博拉病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41559, encryptionId=9e424155935, topicName=埃博拉病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=639b24003788, createdName=tcm107hq, createdTime=Mon Jul 24 23:02:00 CST 2017, time=2017-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1802383, encodeId=0d3c18023838d, content=<a href='/topic/show?id=acfae485578' target=_blank style='color:#2F92EE;'>#科学家发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74855, encryptionId=acfae485578, topicName=科学家发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Fri Aug 11 18:02:00 CST 2017, time=2017-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1960007, encodeId=fd36196000ef7, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Jul 19 05:02:00 CST 2017, time=2017-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869748, encodeId=a3ae1869e480e, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Fri May 19 13:02:00 CST 2017, time=2017-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296468, encodeId=f3e112964683c, content=<a href='/topic/show?id=76f941560d7' target=_blank style='color:#2F92EE;'>#埃博拉病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41560, encryptionId=76f941560d7, topicName=埃博拉病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85aa264, createdName=redcrab, createdTime=Tue Jan 24 08:02:00 CST 2017, time=2017-01-24, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1650363, encodeId=4f9f165036361, content=<a href='/topic/show?id=9e424155935' target=_blank style='color:#2F92EE;'>#埃博拉病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41559, encryptionId=9e424155935, topicName=埃博拉病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=639b24003788, createdName=tcm107hq, createdTime=Mon Jul 24 23:02:00 CST 2017, time=2017-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1802383, encodeId=0d3c18023838d, content=<a href='/topic/show?id=acfae485578' target=_blank style='color:#2F92EE;'>#科学家发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74855, encryptionId=acfae485578, topicName=科学家发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Fri Aug 11 18:02:00 CST 2017, time=2017-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1960007, encodeId=fd36196000ef7, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Jul 19 05:02:00 CST 2017, time=2017-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869748, encodeId=a3ae1869e480e, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Fri May 19 13:02:00 CST 2017, time=2017-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296468, encodeId=f3e112964683c, content=<a href='/topic/show?id=76f941560d7' target=_blank style='color:#2F92EE;'>#埃博拉病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41560, encryptionId=76f941560d7, topicName=埃博拉病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85aa264, createdName=redcrab, createdTime=Tue Jan 24 08:02:00 CST 2017, time=2017-01-24, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1650363, encodeId=4f9f165036361, content=<a href='/topic/show?id=9e424155935' target=_blank style='color:#2F92EE;'>#埃博拉病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41559, encryptionId=9e424155935, topicName=埃博拉病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=639b24003788, createdName=tcm107hq, createdTime=Mon Jul 24 23:02:00 CST 2017, time=2017-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1802383, encodeId=0d3c18023838d, content=<a href='/topic/show?id=acfae485578' target=_blank style='color:#2F92EE;'>#科学家发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74855, encryptionId=acfae485578, topicName=科学家发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Fri Aug 11 18:02:00 CST 2017, time=2017-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1960007, encodeId=fd36196000ef7, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Jul 19 05:02:00 CST 2017, time=2017-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869748, encodeId=a3ae1869e480e, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Fri May 19 13:02:00 CST 2017, time=2017-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296468, encodeId=f3e112964683c, content=<a href='/topic/show?id=76f941560d7' target=_blank style='color:#2F92EE;'>#埃博拉病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41560, encryptionId=76f941560d7, topicName=埃博拉病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85aa264, createdName=redcrab, createdTime=Tue Jan 24 08:02:00 CST 2017, time=2017-01-24, status=1, ipAttribution=)]
    2017-07-19 维他命
  4. [GetPortalCommentsPageByObjectIdResponse(id=1650363, encodeId=4f9f165036361, content=<a href='/topic/show?id=9e424155935' target=_blank style='color:#2F92EE;'>#埃博拉病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41559, encryptionId=9e424155935, topicName=埃博拉病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=639b24003788, createdName=tcm107hq, createdTime=Mon Jul 24 23:02:00 CST 2017, time=2017-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1802383, encodeId=0d3c18023838d, content=<a href='/topic/show?id=acfae485578' target=_blank style='color:#2F92EE;'>#科学家发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74855, encryptionId=acfae485578, topicName=科学家发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Fri Aug 11 18:02:00 CST 2017, time=2017-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1960007, encodeId=fd36196000ef7, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Jul 19 05:02:00 CST 2017, time=2017-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869748, encodeId=a3ae1869e480e, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Fri May 19 13:02:00 CST 2017, time=2017-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296468, encodeId=f3e112964683c, content=<a href='/topic/show?id=76f941560d7' target=_blank style='color:#2F92EE;'>#埃博拉病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41560, encryptionId=76f941560d7, topicName=埃博拉病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85aa264, createdName=redcrab, createdTime=Tue Jan 24 08:02:00 CST 2017, time=2017-01-24, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1650363, encodeId=4f9f165036361, content=<a href='/topic/show?id=9e424155935' target=_blank style='color:#2F92EE;'>#埃博拉病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41559, encryptionId=9e424155935, topicName=埃博拉病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=639b24003788, createdName=tcm107hq, createdTime=Mon Jul 24 23:02:00 CST 2017, time=2017-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1802383, encodeId=0d3c18023838d, content=<a href='/topic/show?id=acfae485578' target=_blank style='color:#2F92EE;'>#科学家发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74855, encryptionId=acfae485578, topicName=科学家发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Fri Aug 11 18:02:00 CST 2017, time=2017-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1960007, encodeId=fd36196000ef7, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Jul 19 05:02:00 CST 2017, time=2017-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869748, encodeId=a3ae1869e480e, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Fri May 19 13:02:00 CST 2017, time=2017-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296468, encodeId=f3e112964683c, content=<a href='/topic/show?id=76f941560d7' target=_blank style='color:#2F92EE;'>#埃博拉病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41560, encryptionId=76f941560d7, topicName=埃博拉病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85aa264, createdName=redcrab, createdTime=Tue Jan 24 08:02:00 CST 2017, time=2017-01-24, status=1, ipAttribution=)]

相关资讯

埃博拉病毒病疫情防控的思考

2014年全球公共卫生热点事件很多,首当其冲的当属全球公共卫生的大事——埃博拉病毒病在西非的猖獗流行。这次埃博拉病毒病并非新发,而是卷土重来,因为早在1976年该病就在中非被发现,以后一直断断续续地流行,2013年底又突然在西非几内亚出现,疫情迅速波及利比里亚和塞拉利昂,来势非常迅猛,还波及美国、西班牙、尼日利亚等6个国家。过去37年(1976—2013)共发病2387例,死亡1590人。而此

高福院士:“小”世界里做大事

约到高福很难,在中国科学院微生物研究所,熟悉他的人都说,高福是所里最忙、最辛苦的人。 翻开高福的简历,中科院院士、中国疾病预防控制中心副主任、中科院微生物研究所病原微生物与免疫学重点实验室主任、国科大医学院院长、中华医学会副会长……数十个头衔加身的他,恨不得24个小时都拿来工作。 可他却笑笑说,自己偶尔还能跑到电影院,去看部热门大片。 如此游刃有余,他是怎么做到的? 留在非洲的秘密

Nature子刊:体外实验证实——中药岩蔷薇强效抵抗HIV和埃博拉病毒

在一项新的研究中,来自德国亥姆霍兹慕尼黑中心的研究人员发现药用植物白瑞木(Cistus incanus,也译作灰白岩蔷薇)的提取物阻止人免疫缺陷病毒(HIV)感染细胞。这种提取物中的抗病毒活性成分抑制HIV病毒蛋白停泊到细胞上。这种提取物中的抗病毒成分也具有抗埃博拉病毒和马尔堡病毒的作用。相关研究结果于2016年2月2日在线发表在Scientific Reports期刊上,论文标题为“Pote

Cell:研究人员可能开发对抗几种埃博拉病毒的单一疗法

在最近发表于Cell的研究中,来自德州大学医学分校(UTMB)、范德堡大学、斯克里普斯研究所和Integral Molecular公司的合作研究团队发现,在一种埃博拉病毒株感染中幸存下来的人的血液中分离的抗体,能够杀死各种类型的埃博拉病毒。 这些发现意义重大,有助于研究人员进一步理解对埃博拉等病毒的免疫反应,可能导向对埃博拉病毒和其他相关病毒的治疗方法。 这项研究使用了在埃博拉本迪布焦毒

PLoS Med:Xpert——埃博拉病毒检测新方法!

 埃博拉病毒在西非国家大肆传播,野外实验室检测埃博拉病毒依赖于复杂的、多步骤的实时逆转录PCR检测;一种精确的RT-PCR检测将减少检测病毒的时间,并且有可能增加检测效率。来自英国、美国、塞拉利昂等国的科研人员评价了一中检测埃博拉病毒的方法Cepheid GeneXpert的性能。这种方法通过静脉穿刺获得全血(WB)和口腔粘膜(BS)测试样本。 此项研究在公共卫生英格兰EVD检

综述:新型抗埃博拉病毒病靶点研究进展

  埃博拉病毒病是由纤丝病毒科(filoviridae)的埃博拉病毒(Ebola virus,EBOV)所引起的一种急性出血性传染病,该病病死率极高,达50%-90%, 是人类最致命的病毒性传染病之一。世界卫生组织统计数据显示,在2013年底至2015年西非埃博拉疫情大爆发中超过22500人感染埃博拉病毒,因感染丧生的人数达9000人。不论是感染病例数量、死亡人

Baidu
map
Baidu
map
Baidu
map